# Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT05960955** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 90 (estimated)

## Conditions studied

- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** AK117
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur-gimeracil-oteracil potassium
- **DRUG:** Docetaxel
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT05960955
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-13
- **Primary completion:** 2024-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960955, "Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05960955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*